---
layout: default
title: Methazolamide
parent: Model Prediction Only (L5)
nav_order: 504
evidence_level: L5
indication_count: 3
---

# Methazolamide
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **3** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Methazolamide: From Glaucoma to Primary Hereditary Glaucoma

## One-Sentence Summary

Methazolamide is a carbonic anhydrase inhibitor; per the mechanistic notes in this evidence pack it belongs to the same drug class as acetazolamide and dorzolamide, previously used in some markets for chronic open-angle glaucoma (the formal original-indication record is a data gap in this pack). The TxGNN model predicts it may be effective for **Primary Hereditary Glaucoma**, but this prediction is currently supported by **0 clinical trials** and **0 publications** — it is a model-score-only signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not confirmed in this evidence pack (data gap); rationale notes suggest glaucoma via carbonic anhydrase inhibition |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 99.83% |
| Evidence Level | L5 |
| Canada Market Status | Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for methazolamide is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on the information that is available, methazolamide is noted as a carbonic anhydrase inhibitor (CAI), the same pharmacological class as acetazolamide and dorzolamide. CAIs lower intraocular pressure by inhibiting carbonic anhydrase in the ciliary body, which reduces aqueous humor production — a well-established mechanism for treating glaucoma.

Primary hereditary glaucoma and the glaucoma indication implied by methazolamide's drug class share the same downstream pathology (elevated intraocular pressure), so a CAI's pressure-lowering effect is mechanistically plausible across glaucoma subtypes regardless of the specific hereditary or structural etiology. This is the basis of the TxGNN prediction's mechanistic link.

That said, this connection is a class-level extrapolation, not evidence specific to methazolamide in primary hereditary glaucoma. No clinical trials or literature in this pack directly test the drug in this indication, and methazolamide's own original approved indication is unconfirmed here (data gap DG001, DG002). The prediction should be treated as hypothesis-generating only.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

Methazolamide is currently **not marketed** in Canada, with no DIN (Drug Identification Number) records in this evidence pack.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted indication (primary hereditary glaucoma) is supported only by the TxGNN model score (99.83%, evidence level L5) with no clinical trials or literature evidence, and the drug's own original indication and MOA are unconfirmed data gaps (DG001, DG002) — one of which (TFDA/label warnings) is Blocking for any safety assessment.

**To proceed, the following is needed:**
- Confirm original approved indication and mechanism of action via DrugBank API (DG002)
- Retrieve TFDA/Health Canada label warnings and contraindications (DG001, currently blocking)
- Targeted literature/clinical trial search specific to methazolamide + primary hereditary glaucoma
- **Note:** among the other candidates in this evidence pack, *congestive heart failure* (rank 2, L4, decision stage S1, "Research Question") has 6 supporting publications including preclinical cardioprotection data and may warrant earlier follow-up than the top-ranked glaucoma prediction.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

